At the recently held “The Tengchong Scientists Forum 2025,” Mr. Fang Wenquan, Chairman of Tianda Group, accepted a joint interview with Yunnan media and, for the first time, systematically outlined the Group’s new development blueprint in Yunnan. Building on a cumulative investment exceeding 1 billion over the past 30 years, Tianda Group officially announced the launch of its “Pharmaceuticals & Healthcare + Fine Phosphorus Chemicals” dual-engine growth strategy, marking the entry of its industrial layout in Yunnan into a new stage of synergistic development and upgraded growth.
Image 1: The Tengchong Scientists Forum 2025
As one of the core engines of the dual-engine strategy, the Group’s listed platform Tianda Pharmaceuticals (0455.HK) will comprehensively deepen its pharmaceutical and healthcare industry presence in Yunnan. Leveraging Yunnan’s reputation as the “Hometown of Chinese Medicinal Herbs” and its unique biological resources as a key advantage, the company will rely on its independently developed “Tianda Standard” quality management system to establish full life-cycle quality control from the source of Chinese medicinal materials to the consumer end, while significantly increasing systematic investment in Yunnan’s authentic medicinal herb industry.
Currently, Tianda Pharmaceuticals’ product portfolio covers key therapeutic areas including cardiovascular & cerebrovascular, pediatrics, respiratory, anti-infective, and anti-tumor treatments, and has cultivated well-recognized brands such as “Herb Valley®” and “Tuokang®”. Going forward, the company will build an integrated online-and-offline traditional Chinese medicine health service platform through “TDMall” and the “TDMall on Cloud” pushing high-quality products and services originating from Yunnan to the national and even global markets.
Image 2: Tianda Products
At the same time, the second engine of the dual strategy — the fine phosphorus chemicals sector — will advance in parallel. Taking the Xundian phosphate mine project as its foundation and through resource integration and technology introduction, the Group will invest in high-value-added fine phosphorus chemical projects, with the goal of building a ¥10-billion-scale industrial cluster and contributing to the transformation and upgrading of Yunnan’s local industrial structure.
Mr. Fang Wenquan emphasized, ““Tianda for Health!” is not only our brand promise but also the guiding principle for our industrial actions. We will continue to transform Yunnan’s ecological and resource advantages into high-quality health products and industrial momentum.”
The release of this strategy further clarifies Tianda Pharmaceuticals’ determination to use Yunnan as its strategic base and strengthen its market position in the pharmaceutical and healthcare sector, while demonstrating Tianda Group’s long-term confidence and commitment to Yunnan.
About Tianda Pharmaceuticals Limited
Tianda Pharmaceuticals Limited (“Tianda Pharma”, listed on the Hong Kong Stock Exchange, stock code: 0455.HK) implements the following development strategies: development of TCM as its foundation, development of innovative drugs and medical technologies, as well as development of high-quality medical and healthcare services, striving to become a leading pharmaceutical enterprise that sets its footholds in China while seeking to expand its presence worldwide.
Media Enquiries
Tianda Pharmaceuticals Limited
Corporate Communications
Tel: +852 2295 0303
Email: corpcomm@tianda.com